title: Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
abstract: BACKGROUND
  It is unclear whether there is a difference in the efficacy of treatment by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) between patients with postoperative recurrent non-small-cell lung cancer (NSCLC) and those with stage IV NSCLC harboring EGFR mutations.
  
  
  METHODS
  The records of NSCLC patients harboring EGFR mutations who were treated with gefitinib or erlotinib were retrospectively reviewed, and the treatment outcomes were evaluated. Moreover, we performed an immunohistochemical analysis of PD-L1 expression in tumor lesions of the postoperative recurrence group.
  
  
  RESULTS
  In 205 patients, both the progression-free survival (PFS) time (9.4 vs. 16.9 months) and the median survival time (24.7 vs. 37.4 months) were significantly longer in the postoperative group than in the stage IV group. Additionally, multivariate analysis identified that postoperative recurrence was an independent predictor of PFS and overall survival, as were performance status and smoking status. The PFS durations were 15.7 and 16.6 months for the high- and low-PD-L1 expression groups, respectively, and no significant difference was observed (P = 0.73).
  
  
  CONCLUSIONS
  The findings of this study provide a valuable rationale for considering postoperative recurrence as a predictive factor for favorable PFS and overall survival in patients with NSCLC harboring activating EGFR mutations who receive EGFR-TKIs.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Igawa
authors.forename: Shiichiro
authors.initials: S
authors.lastname: Ryuge
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ichinoe
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Nakashima
authors.forename: Sakiko
authors.initials: S
authors.lastname: Otani
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Nakahara
authors.forename: Tomoya
authors.initials: T
authors.lastname: Fukui
authors.forename: Jiichiro
authors.initials: J
authors.lastname: Sasaki
authors.forename: Masaru
authors.initials: M
authors.lastname: Kubota
authors.forename: Masato
authors.initials: M
authors.lastname: Katagiri
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Murakumo
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Satoh
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sato
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Masuda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000627:therapeutic use; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics; D011184:Postoperative Period; D011799:Quinazolines / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; D000077156:Gefitinib